Beschreibung
Carbamazepine markedly reduces warfarin plasma concentrations, potentially resulting in sub-therapeutic anticoagulation and increased thromboembolic risk.
Mechanismus
Carbamazepine is a potent inducer of CYP2C9 and CYP3A4, the primary enzymes responsible for warfarin metabolism, accelerating its clearance.
Klinische Bedeutung
INR can drop significantly; thrombotic events (stroke, PE) have been reported when warfarin doses were not increased proportionally.
Maßnahmen
Monitor INR closely when initiating or stopping carbamazepine; warfarin dose increases of 50–100% may be required. Consider alternative anticonvulsants if feasible.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.